FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2966923673> ?p ?o ?g. }

• W2966923673 endingPage "1361" @default.
• W2966923673 startingPage "1352" @default.
• W2966923673 abstract "Immune checkpoint inhibitors, such as antibody against programmed cell death protein (PD-1), have demonstrated antitumour effects in patients with malignancies, including oesophageal cancer. A lymphocytic reaction observed by pathological examination is a manifestation of the host immune response to tumour cells. It was hypothesized that a stronger lymphocytic reaction to tumours might be associated with favourable prognosis in oesophageal cancer.Using a database of resected oesophageal cancers, four morphological components of lymphocytic reactions (peritumoral, intranest, lymphoid and stromal) to tumours were evaluated in relation to clinical outcome, PD-1 expression by immunohistochemistry and total lymphocyte count in blood.Resected oesophageal cancer specimens from 436 patients were included in the study. Among the four morphological components, only peritumoral reaction was associated with patient prognosis (multivariable P for trend <0·001); patients with a higher peritumoral reaction had significantly longer overall survival than those with a lower reaction (multivariable hazard ratio 0·48, 95 per cent c.i. 0·34 to 0·67). The prognostic effect of peritumoral reaction was not significantly modified by other clinical variables (all P for interaction >0·050). Peritumoral reaction was associated with total lymphocyte count in the blood (P < 0·001), supporting the relationship between local immune response and systemic immune competence. In addition, higher morphological peritumoral reaction was associated with high PD-1 expression on lymphocytes in tumours (P = 0·034).These findings should help to improve risk-adapted therapeutic strategies and help stratify patients in the future clinical setting of immunotherapy for oesophageal cancer.Los inhibidores de los puntos de control inmunitario (checkpoints) (p.ej. los anticuerpos anti-PD-1) han demostrado efectos antitumorales en pacientes con tumores malignos, incluido el cáncer de esófago. La reacción linfocítica detectada en estudios anatomopatológicos es una manifestación de la respuesta inmune del huésped a las células tumorales. Se estableció la hipótesis de que una mayor reacción linfocítica a los tumores podría asociarse con un mejor pronóstico en el cáncer de esófago. MÉTODOS: Usando una base de datos de 436 cánceres de esófago resecados, se evaluaron cuatro componentes morfológicos (peritumoral, intra-epitelial, linfoide y estromal) de las reacciones linfocíticas a tumores en relación con los resultados clínicos, la expresión inmunohistoquímica de PD-1 y el recuento total de linfocitos en sangre.De los cuatro componentes, solamente la reacción peritumoral se asoció con el pronóstico del paciente (P multivariable para tendencia < 0,001): los pacientes con mayor reacción peritumoral presentaron una supervivencia global significativamente más prolongada que aquellos pacientes con menor reacción peritumoral (cociente de riesgos instantáneos multivariable, hazard ratio, HR: 0,48; i.c. del 95%: 0,34 -0,67; P <0,001). El efecto pronóstico de la reacción peritumoral no se modificó significativamente por otras variables clínicas (todas las P para la interacción > 0,05). La reacción peritumoral se asoció con el recuento total de linfocitos en la sangre (P < 0,001), lo que respalda la relación entre la respuesta inmune local y la competencia inmune sistémica. Además, una elevada reacción morfológica peritumoral se asoció con una alta expresión de PD-1 en linfocitos tumorales (P = 0,034). CONCLUSIÓN: Estos hallazgos deberían ayudar a mejorar las estrategias terapéuticas adaptadas al riesgo y contribuir a estratificar a los pacientes en el entorno clínico futuro de la inmunoterapia para los pacientes con cáncer de esófago." @default.
• W2966923673 created "2019-08-22" @default.
• W2966923673 creator A5001629581 @default.
• W2966923673 creator A5011238306 @default.
• W2966923673 creator A5015480910 @default.
• W2966923673 creator A5018669075 @default.
• W2966923673 creator A5021251912 @default.
• W2966923673 creator A5033294815 @default.
• W2966923673 creator A5047981191 @default.
• W2966923673 creator A5053407034 @default.
• W2966923673 creator A5060949471 @default.
• W2966923673 creator A5064146636 @default.
• W2966923673 creator A5069774184 @default.
• W2966923673 creator A5072733384 @default.
• W2966923673 creator A5075398219 @default.
• W2966923673 creator A5079811694 @default.
• W2966923673 creator A5084734266 @default.
• W2966923673 creator A5085621012 @default.
• W2966923673 date "2019-08-15" @default.
• W2966923673 modified "2023-10-14" @default.
• W2966923673 title "Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer" @default.
• W2966923673 cites W1583432150 @default.
• W2966923673 cites W1784648447 @default.
• W2966923673 cites W1971622516 @default.
• W2966923673 cites W2011143480 @default.
• W2966923673 cites W2041560748 @default.
• W2966923673 cites W2049099826 @default.
• W2966923673 cites W2067974743 @default.
• W2966923673 cites W2069505409 @default.
• W2966923673 cites W2088741578 @default.
• W2966923673 cites W2095724207 @default.
• W2966923673 cites W2096151993 @default.
• W2966923673 cites W2096322385 @default.
• W2966923673 cites W2151444514 @default.
• W2966923673 cites W2155477398 @default.
• W2966923673 cites W2461155246 @default.
• W2966923673 cites W2515679023 @default.
• W2966923673 cites W2521930878 @default.
• W2966923673 cites W2555620213 @default.
• W2966923673 cites W2559382297 @default.
• W2966923673 cites W2585325504 @default.
• W2966923673 cites W2586306658 @default.
• W2966923673 cites W2596604644 @default.
• W2966923673 cites W2599546837 @default.
• W2966923673 cites W2616677257 @default.
• W2966923673 cites W2725398806 @default.
• W2966923673 cites W2735904407 @default.
• W2966923673 cites W2743787112 @default.
• W2966923673 cites W2759258394 @default.
• W2966923673 cites W2767857925 @default.
• W2966923673 cites W2790175021 @default.
• W2966923673 cites W2798160602 @default.
• W2966923673 cites W2808750176 @default.
• W2966923673 cites W2872997440 @default.
• W2966923673 cites W2902771169 @default.
• W2966923673 cites W2911752971 @default.
• W2966923673 cites W2991564522 @default.
• W2966923673 doi "https://doi.org/10.1002/bjs.11301" @default.
• W2966923673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31414718" @default.
• W2966923673 hasPublicationYear "2019" @default.
• W2966923673 type Work @default.
• W2966923673 sameAs 2966923673 @default.
• W2966923673 citedByCount "11" @default.
• W2966923673 countsByYear W29669236732020 @default.
• W2966923673 countsByYear W29669236732021 @default.
• W2966923673 countsByYear W29669236732022 @default.
• W2966923673 countsByYear W29669236732023 @default.
• W2966923673 crossrefType "journal-article" @default.
• W2966923673 hasAuthorship W2966923673A5001629581 @default.
• W2966923673 hasAuthorship W2966923673A5011238306 @default.
• W2966923673 hasAuthorship W2966923673A5015480910 @default.
• W2966923673 hasAuthorship W2966923673A5018669075 @default.
• W2966923673 hasAuthorship W2966923673A5021251912 @default.
• W2966923673 hasAuthorship W2966923673A5033294815 @default.
• W2966923673 hasAuthorship W2966923673A5047981191 @default.
• W2966923673 hasAuthorship W2966923673A5053407034 @default.
• W2966923673 hasAuthorship W2966923673A5060949471 @default.
• W2966923673 hasAuthorship W2966923673A5064146636 @default.
• W2966923673 hasAuthorship W2966923673A5069774184 @default.
• W2966923673 hasAuthorship W2966923673A5072733384 @default.
• W2966923673 hasAuthorship W2966923673A5075398219 @default.
• W2966923673 hasAuthorship W2966923673A5079811694 @default.
• W2966923673 hasAuthorship W2966923673A5084734266 @default.
• W2966923673 hasAuthorship W2966923673A5085621012 @default.
• W2966923673 hasConcept C121608353 @default.
• W2966923673 hasConcept C126322002 @default.
• W2966923673 hasConcept C143998085 @default.
• W2966923673 hasConcept C159654299 @default.
• W2966923673 hasConcept C203014093 @default.
• W2966923673 hasConcept C204232928 @default.
• W2966923673 hasConcept C207103383 @default.
• W2966923673 hasConcept C207886595 @default.
• W2966923673 hasConcept C2777701055 @default.
• W2966923673 hasConcept C2777761686 @default.
• W2966923673 hasConcept C44249647 @default.
• W2966923673 hasConcept C71924100 @default.
• W2966923673 hasConcept C8891405 @default.
• W2966923673 hasConcept C90924648 @default.

• next